BIO-TECHNE Corp (TECH) financials: revenue, earnings and cash flow
Fiscal 2017–2026 + TTM · from SEC filings · data as of November 13, 2026
Summary
Net income in fiscal 2026 was $182M, a net margin of 15.0%; the best year in this period was 2023 with $285M.
Over the twelve months to September 30, 2026, revenue was $1.2B and net income $172M.
Free cash flow was $263M in fiscal 2026 and positive in 9 of the 10 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2B | $1.2B | $1.2B | $1.2B | $1.1B | $1.1B | $931M | $739M | $714M | $643M | — |
| Gross profit | $808M | $799M | $790M | $770M | $770M | $756M | $633M | $483M | $473M | $432M | — |
| Operating income | $241M | $252M | $102M | $207M | $299M | $297M | $237M | $157M | $147M | $136M | — |
| Net income | $172M | $182M | $73M | $168M | $285M | $272M | $140M | $229M | $96M | $126M | $49M |
| EPS (diluted) | $1.09 | $1.16 | $0.46 | $1.05 | $1.76 | $1.66 | $0.87 | $1.46 | $0.62 | $0.83 | — |
| R&D | $97M | $95M | $99M | $97M | $92M | $87M | $71M | $65M | $62M | $55M | — |
| Revenue growth | — | −0.4% | +5.2% | +2.0% | +2.8% | +18.8% | +26.0% | +3.5% | +11.0% | — | — |
Cash flow
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $338M | $292M | $288M | $299M | $254M | $325M | $352M | $205M | $182M | $170M | — |
| Capital spending | -$29M | -$29M | -$31M | -$63M | -$38M | -$45M | -$44M | -$52M | -$25M | -$21M | — |
| Free cash flow | $308M | $263M | $257M | $236M | $216M | $280M | $308M | $153M | $156M | $149M | — |
| Dividends paid | $50M | $50M | $50M | $50M | $50M | $50M | $50M | $49M | $48M | $48M | — |
| Buybacks | — | $42M | $276M | $80M | $20M | $161M | $43M | $50M | $15M | $0 | — |
| Stock-based pay | $43M | $41M | $41M | $38M | $39M | $42M | $49M | $32M | $32M | $28M | — |
Balance sheet
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $265M | $162M | $153M | $204M | $247M | $232M | $147M | $101M | $122M | — |
| Debt | — | $289M | $790M | $739M | $455M | $326M | $421M | $434M | $505M | $339M | — |
| Equity | — | $2.1B | $1.9B | $2.1B | $2.0B | $1.7B | $1.6B | $1.4B | $1.2B | $1.1B | — |
| Total assets | — | $2.6B | $2.6B | $2.7B | $2.6B | $2.3B | $2.3B | $2.0B | $1.9B | $1.6B | — |
| Shares (diluted) | 158M | 157M | 160M | 161M | 162M | 164M | 162M | 158M | 156M | 152M | — |
Margins and returns
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 65.8% | 65.8% | 64.8% | 66.4% | 67.7% | 68.4% | 68.0% | 65.4% | 66.3% | 67.2% | — |
| Operating margin | 19.6% | 20.7% | 8.4% | 17.8% | 26.3% | 26.8% | 25.5% | 21.3% | 20.5% | 21.2% | — |
| Net margin | 14.0% | 15.0% | 6.0% | 14.5% | 25.1% | 24.6% | 15.1% | 31.0% | 13.5% | 19.6% | — |
| FCF margin | 25.1% | 21.7% | 21.0% | 20.4% | 19.0% | 25.4% | 33.1% | 20.8% | 21.9% | 23.2% | — |
| ROIC | — | 7.9% | 2.8% | 6.7% | 10.4% | 12.8% | 11.3% | 7.2% | 7.5% | 7.6% | — |
| ROE | — | 8.6% | 3.8% | 8.1% | 14.5% | 16.0% | 9.0% | 16.6% | 8.2% | 11.7% | — |
Frequently asked questions
What is BIO-TECHNE’s annual revenue?
$1.2B in fiscal 2026 and $1.2B over the twelve months to September 30, 2026.
How much profit does BIO-TECHNE make?
Net income was $182M in fiscal 2026 (net margin 15.0%).
Is BIO-TECHNE’s revenue growing?
No: revenue fell 0.4% in fiscal 2026 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.